Autologous bone marrow transplants: Different indications in Europe and North America

N. C.R.P. Gorin. Gale; J. O. Armitage; K. Antman; F. Appelbaum; C. S. August; A. K. Burnett; K. Dicke; R. P. Gale; J. M. Goldman; A. H. Goldstone; J. Graham-Pole; A. Hagenbeek; O. Hartmann; P. Herve; G. H. Herzig; R. H. Herzig; D. D. Hurd; S. Jagannath

Autologous bone marrow transplants: Different indications in Europe and North America

N. C.R.P. Gorin. Gale, J. O. Armitage, K. Antman, F. Appelbaum, C. S. August, A. K. Burnett, K. Dicke, R. P. Gale, J. M. Goldman, A. H. Goldstone, J. Graham-Pole, A. Hagenbeek, O. Hartmann, P. Herve, G. H. Herzig, R. H. Herzig, D. D. Hurd, S. Jagannath

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The International Autologous Bone Marrow Transplant Registry surveyed activity at 112 centres worldwide. Transplants increased from 265 in 1981 to over 1200 in 1987. Diseases most frequently treated by autotransplantation included non-Hodgkin lymphoma (22%), acute myelogenous leukaemia (19%), acute lymphoblastic leukaemia (15%), Hodgkin disease (15%), and neuroblastoma (5%). There were striking differences in the use of autotransplants between North America and Europe. Autotransplants for lymphomas and solid tumours comprised 94% of North American Autotransplants but only 41% of those in Europe. In contrast, leukaemia was the indication in 59% of Europeans but only 6% of North Americans. 65% of leukaemia autotransplants in Europe were done in first remission compared with 8% in North America. There were also differences in age and types of lymphoma autotransplanted - Burkitt and lymphoblastic lymphoma in young persons in Europe, versus large-cell lymphomas in older persons in North America.

Original language	English (US)
Pages (from-to)	317-318
Number of pages	2
Journal	Lancet
Volume	2
Issue number	8658
State	Published - 1989
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Cite this

Gorin. Gale, N. C. R. P., Armitage, J. O., Antman, K., Appelbaum, F., August, C. S., Burnett, A. K., Dicke, K., Gale, R. P., Goldman, J. M., Goldstone, A. H., Graham-Pole, J., Hagenbeek, A., Hartmann, O., Herve, P., Herzig, G. H., Herzig, R. H., Hurd, D. D., & Jagannath, S. (1989). Autologous bone marrow transplants: Different indications in Europe and North America. Lancet, 2(8658), 317-318.

@article{1b64aff091464aa4b5085e7582862595,

title = "Autologous bone marrow transplants: Different indications in Europe and North America",

abstract = "The International Autologous Bone Marrow Transplant Registry surveyed activity at 112 centres worldwide. Transplants increased from 265 in 1981 to over 1200 in 1987. Diseases most frequently treated by autotransplantation included non-Hodgkin lymphoma (22%), acute myelogenous leukaemia (19%), acute lymphoblastic leukaemia (15%), Hodgkin disease (15%), and neuroblastoma (5%). There were striking differences in the use of autotransplants between North America and Europe. Autotransplants for lymphomas and solid tumours comprised 94% of North American Autotransplants but only 41% of those in Europe. In contrast, leukaemia was the indication in 59% of Europeans but only 6% of North Americans. 65% of leukaemia autotransplants in Europe were done in first remission compared with 8% in North America. There were also differences in age and types of lymphoma autotransplanted - Burkitt and lymphoblastic lymphoma in young persons in Europe, versus large-cell lymphomas in older persons in North America.",

author = "{Gorin. Gale}, {N. C.R.P.} and Armitage, {J. O.} and K. Antman and F. Appelbaum and August, {C. S.} and Burnett, {A. K.} and K. Dicke and Gale, {R. P.} and Goldman, {J. M.} and Goldstone, {A. H.} and J. Graham-Pole and A. Hagenbeek and O. Hartmann and P. Herve and Herzig, {G. H.} and Herzig, {R. H.} and Hurd, {D. D.} and S. Jagannath",

note = "Funding Information: Our work is supported by grant CA23175 from the NCI, NIH, USPHS, DHHS, and a grant from the Center for Advanced Studies in Leukemia. R. P. G. is the Wald Foundation Scholar in Biomedical Communications. Katharine Fry typed the script; Emanuel Maidenberg provided technical assistance.",

year = "1989",

language = "English (US)",

volume = "2",

pages = "317--318",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8658",

}

TY - JOUR

T1 - Autologous bone marrow transplants

T2 - Different indications in Europe and North America

AU - Gorin. Gale, N. C.R.P.

AU - Armitage, J. O.

AU - Antman, K.

AU - Appelbaum, F.

AU - August, C. S.

AU - Burnett, A. K.

AU - Dicke, K.

AU - Gale, R. P.

AU - Goldman, J. M.

AU - Goldstone, A. H.

AU - Graham-Pole, J.

AU - Hagenbeek, A.

AU - Hartmann, O.

AU - Herve, P.

AU - Herzig, G. H.

AU - Herzig, R. H.

AU - Hurd, D. D.

AU - Jagannath, S.

N1 - Funding Information: Our work is supported by grant CA23175 from the NCI, NIH, USPHS, DHHS, and a grant from the Center for Advanced Studies in Leukemia. R. P. G. is the Wald Foundation Scholar in Biomedical Communications. Katharine Fry typed the script; Emanuel Maidenberg provided technical assistance.

PY - 1989

Y1 - 1989

N2 - The International Autologous Bone Marrow Transplant Registry surveyed activity at 112 centres worldwide. Transplants increased from 265 in 1981 to over 1200 in 1987. Diseases most frequently treated by autotransplantation included non-Hodgkin lymphoma (22%), acute myelogenous leukaemia (19%), acute lymphoblastic leukaemia (15%), Hodgkin disease (15%), and neuroblastoma (5%). There were striking differences in the use of autotransplants between North America and Europe. Autotransplants for lymphomas and solid tumours comprised 94% of North American Autotransplants but only 41% of those in Europe. In contrast, leukaemia was the indication in 59% of Europeans but only 6% of North Americans. 65% of leukaemia autotransplants in Europe were done in first remission compared with 8% in North America. There were also differences in age and types of lymphoma autotransplanted - Burkitt and lymphoblastic lymphoma in young persons in Europe, versus large-cell lymphomas in older persons in North America.

AB - The International Autologous Bone Marrow Transplant Registry surveyed activity at 112 centres worldwide. Transplants increased from 265 in 1981 to over 1200 in 1987. Diseases most frequently treated by autotransplantation included non-Hodgkin lymphoma (22%), acute myelogenous leukaemia (19%), acute lymphoblastic leukaemia (15%), Hodgkin disease (15%), and neuroblastoma (5%). There were striking differences in the use of autotransplants between North America and Europe. Autotransplants for lymphomas and solid tumours comprised 94% of North American Autotransplants but only 41% of those in Europe. In contrast, leukaemia was the indication in 59% of Europeans but only 6% of North Americans. 65% of leukaemia autotransplants in Europe were done in first remission compared with 8% in North America. There were also differences in age and types of lymphoma autotransplanted - Burkitt and lymphoblastic lymphoma in young persons in Europe, versus large-cell lymphomas in older persons in North America.

UR - http://www.scopus.com/inward/record.url?scp=0024383395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024383395&partnerID=8YFLogxK

M3 - Article

C2 - 2569113

AN - SCOPUS:0024383395

SN - 0140-6736

VL - 2

SP - 317

EP - 318

JO - The Lancet

JF - The Lancet

IS - 8658

ER -

Autologous bone marrow transplants: Different indications in Europe and North America

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this